A closer look at “Vera Therapeutics' Trutakna Shows Breakthrough Results in Phase 3 IgAN Trial: Key Data Rev”, exactly as the source publishes it. Vera Therapeutics has announced compelling final results from its Phase 3 trial of Trutakna (formerly VT-110), a novel therapy targeting immunoglobulin A n... Vera Therapeutics has announced compelling final results from its Phase 3 trial of Trutakna (formerly VT-110), a novel therapy targeting immunoglobulin A nephropathy (IgAN), a leading cause of kidney failure. The trial, which included 482 patients across North America and Europe, demonstrated that Trutakna significantly stabilized kidney function over 12 months, with a 67% reduction in the risk of kidney disease progression or death compared to placebo.
Patients receiving Trutakna also showed marked improvements in proteinuria levels—reducing urinary protein excretion by an average of 58%. These outcomes represent a major advancement in treating IgAN, a condition historically lacking effective therapies. For the complete material, the listing points back to the source inside the network.